Skip to main content

Omnicell, Inc. (OMCL) Stock Analysis

SellModerate Confidence

Healthcare · Health Information Services

Sell if holding. Momentum 4.1/10 is below the 5.0 floor at $43.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5).

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an... Read more

$43.22+23.4% A.UpsideScore 5.1/10#11 of 13 Health Information Services
QualityF-score8 / 9FCF yield5.73%
Stop $40.19Target $53.32(analyst − 13%)A.R:R 1.6:1
Analyst target$61.29+41.8%7 analysts
$53.32our TP
$43.22price
$61.29mean
$70

Sell if holding. Momentum 4.1/10 is below the 5.0 floor at $43.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Omnicell, Inc.

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Analyst upside: 23%
Risks
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5)

Key Metrics

P/E (TTM)98.2
P/E (Fwd)19.7
Mkt Cap$2.0B
EV/EBITDA26.2
Profit Mgn1.7%
ROE1.6%
Rev Growth14.9%
Beta0.96
DividendNone
Rating analysts14

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C3.09bearish
IV56%elevated
Max Pain$35-19.0% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
3.1
Value Rank
4.2
Quality Rank
4.2
GatesMomentum 4.1<4.5A.R:R 1.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 72d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
39 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $35.50Resistance $46.89

Price Targets

$40
$53
A.Upside+23.4%
A.R:R1.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 4.1/10 — below 4.5 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-07-30 (72d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OMCL stock a buy right now?

Sell if holding. Momentum 4.1/10 is below the 5.0 floor at $43.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $40.19. Score 5.1/10, moderate confidence.

What is the OMCL stock price target?

Take-profit target: $53.32 (+23.4% upside). Prior stop was $40.19. Stop-loss: $40.19.

What are the risks of investing in OMCL?

V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5).

Is OMCL overvalued or undervalued?

Omnicell, Inc. trades at a P/E of 98.2 (forward 19.7). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about OMCL?

14 analysts cover OMCL with a consensus score of 4.1/5. Average price target: $61.

What does Omnicell, Inc. do?Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and...

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Related stocks: WAY (Waystar Holding Corp.) · HQY (HealthEquity, Inc.) · HNGE (Hinge Health, Inc.) · PRVA (Privia Health Group, Inc.) · MMED (MiniMed Group, Inc.)